{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:48:00Z","timestamp":1768772880088,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ijcard.2018.03.034","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T17:36:15Z","timestamp":1520876175000},"page":"130-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators"],"prefix":"10.1016","volume":"261","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.03.034_bb0005","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0010","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","volume":"71","author":"Yancy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijcard.2017.02.015","article-title":"Effectiveness of a management program for outpatient clinic or remote titration of beta-blockers in CRT patients: the RESTORE study","volume":"236","author":"D'Onofrio","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ejhf.252","article-title":"Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling","volume":"17","author":"G\u00fcder","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"9","key":"10.1016\/j.ijcard.2018.03.034_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002982","article-title":"Do general practitioners follow treatment recommendations from guidelines in their decisions on heart failure management? A cross-sectional study","volume":"3","author":"Swennen","year":"2013","journal-title":"BMJ Open"},{"issue":"11 Suppl","key":"10.1016\/j.ijcard.2018.03.034_bb0040","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","article-title":"Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF","volume":"3","author":"Heywood","year":"2010","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0050","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0060","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ejhf.937","article-title":"Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD treatment trial","volume":"20","author":"Lam","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0075","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0080","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0085","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0095","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0100","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0105","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0110","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0120","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0125","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0135","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group","volume":"342","author":"Waagstein","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.034_bb0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cardfail.2003.08.003","article-title":"Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial","volume":"9","author":"Packer","year":"2003","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2004.10.032","article-title":"What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the metoprolol controlled release\/extended release randomized intervention trial in chronic heart failure (MERIT-HF)","volume":"45","author":"Gullestad","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.034_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jchf.2015.09.002","article-title":"Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial","volume":"4","author":"Fiuzat","year":"2016","journal-title":"JACC Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318311525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318311525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T22:01:56Z","timestamp":1533160916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318311525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":30,"alternative-id":["S0167527318311525"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.034","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}